REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai > Cyclopeptides > 2 Peptide Repeating Units In Known Peptide Chain 2 Peptide Repeating Units In Known Peptide Chain2 Peptide Repeating Units In Known Peptide Chain patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/25/07 - 20070021354 - Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing ... 01/25/07 - 20070021353 - Alpha ketoamide compounds as cysteine protease inhibitors The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them. ... 01/18/07 - 20070015716 - Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs Disclosed are methods for providing enhanced systemic blood concentrations of orally delivered drugs that are incompletely translocated across the intestinal wall of an animal. Also disclosed are methods for the sustained release of drugs, whether poorly or readily bioavailable via oral delivery to animals. Still further, disclosed are compounds and ... 01/11/07 - 20070010457 - Caspase inhibitors and uses thereof The present invention relates to novel classes of compounds of formula I which are caspase and TNF-alpha inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting caspase and TNF-alpha activity and consequently, can be ... 01/04/07 - 20070004646 - Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors Selected heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, compositions, and methods for inhibiting retroviral proteases, such as human immunodeficiency virus ... 01/04/07 - 20070004645 - Aromatic amides as potentiators of bioefficacy of anti-infective drugs The present invention relates to an aromatic substituted pentadienoic acid amides and there use in combination of specific amounts of aromatic amides i.e. 4-alkyl-5-(substituted phenyl)-2(E),4(E)-pentadienoic acid amides, its geometrical isomers or their dihydro or tetrahydro derivatives and an anti-infective drug useful in potentiating the bioefficacy of antiinfective drug. The combination ... 01/04/07 - 20070004644 - Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia The present invention provides compositions adapted to enhance reverse cholesterol transport in mammals. The compositions are suitable for oral delivery and useful in the treatment and/or prevention of hypercholesterolemia, atherosclerosis and associated cardiovascular diseases. ... 01/04/07 - 20070004643 - Alpha-ketoamide derivative, and production method and use thereof R3 is a lower alkyl optionally substituted by a halogen, a lower alkoxy or a phenyl, or a fused polycyclic hydrocarbon group), which is well absorbed orally, exhibits durability of good blood level and has potent calpain inhibitory activity. ... 12/28/06 - 20060293248 - Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for treating conditions mediated by DPIV or DPIV-like enzymes, such as cancer and tumors. In a more preferred embodiment, the compounds of the present invention are useful for the ... 12/21/06 - 20060287252 - Substances k01-0509 and process for producing the same A microorganism belonging to the genus Streptomyces and being capable of producing substance K01-0509-A1 and/or substance K01-0509-A2 is cultured in a medium. Then, the substance K01-0509-A1 and/or the substance K01-0509-A2 having been thus accumulated in the liquid culture medium are collected from the medium. It is expected that the obtained ... 12/21/06 - 20060287251 - Combination therapy for glycaemic control The present invention relates to method of treatment, in particular to a method for the treatment of diabetes mellitus, especially non-insulin dependent diabetes mellitus (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus the predi,betic state and/or obesity and to compositions for use in s ch method. ... 12/14/06 - 20060281690 - Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period The invention relates to unsolvated and host-guest solvated crystalline forms of (2E,4S)-4-[(N-{[(2R)-1-isopropylpiperidin-2-yl]-carbonyl}-3-methyl-L-valyl)(methyl)amino]-2,5-dimethylhex-2-enoic acid, E7974, and their therapeutic uses. Pharmaceutical compositions containing crystalline forms of E7974 and a pharmaceutically acceptable carrier represent one embodiment of the invention. The invention also relates to methods for treating cancer, an inflammatory disorder, an autoimmune ... 12/07/06 - 20060276410 - Compounds and methods for selective inhibition of dipeptidyl peptidase-iv as well as pharmaceutically acceptable salts thereof, cyclic isomers thereof, prodrugs thereof, and solvates thereof, where all the variables are defined herein. These compounds can be used, alone or in combination with other drugs, for the treatment of diabetes and related diseases. ... 11/30/06 - 20060270609 - Inhibitors for the soluble epoxide hydrolase Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases. ... 11/30/06 - 20060270608 - Drugs for chronic pain R1c is H or alkyl with from 1 to 5 carbon atoms; B is such that its precursor is selected from amino acids, hydroxy acids, polyalcohol, compounds; C is a bivalent radical containing an aliphatic, heterocyclic or aromatic radical. ... 11/23/06 - 20060264381 - Methods of treating obsessive compulsive disorder An subjects with obsessive compulsive disorder is treated. In one embodiment, the subject is administered a compound down regulates Group I mGluR signaling. In another embodiment, the subject is administered a compound that down regulates endocannabinoid signaling. The subject that has obsessive compulsive disorder can further have at least one ... 11/23/06 - 20060264380 - Compounds and methods for promoting angiogenesis Angiogenesis may be initiated or increased through the use of gamma-secretase inhibitors. The gamma-secretase inhibitor can be a dipeptide class, sulfonamide class, transition state mimic class, benzodiazepine class, or benzocaprolactam class gamma secretase inhibitor. Methods for initiating and increasing angiogenesis are used for disease prevention and treatment as well as ... 11/16/06 - 20060258598 - Alpha-keto carbonyl calpain inhibitors The present invention relates to novel α-keto carbonyl calpain inhibitors for the treatment of neurodegenerative diseases and neuromuscular diseases including Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and other muscular dystrophies. Disuse atrophy and general muscle wasting can also be treated. Diseases of the eye, in particular cataract, can be treated ... 11/09/06 - 20060252701 - Modulation of central nervous system (cns) dipeptidyl peptidase iv (dpiv)-like activity for the treatment of neurological and neuropsychological disorders The present invention discloses a method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain. Administration of a suitable DP IV inhibitor causes the reduction of activity in the enzyme dipeptidyl peptidase (DP IV ... 10/19/06 - 20060234947 - Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X-Y or Y-X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such ... 10/19/06 - 20060234946 - Use of telmisartan for the prevention and treatment of vascular headache The present invention relates to a method for the prophylaxis of vascular headaches which do not originate from hypertension, especially migraine, the method comprising administration of telmisartan to a subject in need of such a treatment. The present invention relates also to a method for the prophylaxis of vascular headaches, ... 10/12/06 - 20060229257 - Multivalent metal salts of boronic acids Salts of a pharmaceutically acceptable divalent metal and an organoboronic acid drug. Examples of such metals are calcium, magnesium and zinc. The organoboronic acid drug may be a boropeptide protease inhibitor. The salts may be formulated in oral dosage form. ... 10/12/06 - 20060229256 - Enternal administration of arginine and glutamine for abnormal vascular proliferation The subject invention provides a method and compositions for preventing and/or treating abnormal vascular proliferation in a human infant where the method involves enterally administering arginine and glutamine to the infant in about equimolar amounts to provide a total amount of arginine and glutamine that is effective to prevent or ... 10/12/06 - 20060229255 - Identification of n-alkylglycine trimers for induction of apoptosis N-alkylglycine trimers with the capacity to arrest the cell cycle in human cancer cells and to induce apoptosis useful for the therapy of cancer. Combination of said N-alkylglycine trimers with taxol. ... 10/12/06 - 20060229254 - Compounds having prolyl oligopeptidase inhibitory activity wherein X, R1, R2 and R3 are as defined in the disclosure, or a pharmaceutically acceptable salt or ester thereof, useful as a prolyl oligopeptidase inhibitor. The compounds can be used for the treatment of diseases or conditions where prolyl oligopeptidase inhibitors are indicated to be effective, for example for ... 10/05/06 - 20060223761 - Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease Also disclosed pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions. ... 09/28/06 - 20060217321 - Compositions to improve tic disorders Tic disorders can be improved by administering theanine, an amino acid that crosses the blood-brain barrier, or a dipeptide consisting of theanine and a different amino acid. In addition, these compositions can be added to foods and drinks or pharmaceuticals. ... 09/21/06 - 20060211630 - Novel synthetic compounds, processes of manufacture and uses in the treatment of integrin-mediated disorders This invention relates to nitroproline derivative compounds and procedures for their preparation and the preparation of pharmaceutical compositions containing the compounds. The invention also relates to the administration of compounds of the invention as agents for the treatment of mammalian diseases whose pathogenic and pathophysiological mechanisms depend on or are ... 09/14/06 - 20060205675 - Combinations of dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus A method for the treatment of diabetes mellitus, especially Type 2 diabetes and conditions associated with diabetes mellitus in a mammal such as a human, which method comprises administering an effective, non-toxic and pharmaceutically acceptable amount of a dipeptidyl peptidase IV inhibitor and another antidiabetic agent, to a mammal in ... 09/14/06 - 20060205674 - Prodrugs containing novel bio-cleavable linkers The invention provides the compounds of formula (I) or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one or more of pharmaceutically acceptable carriers, vehicles or diluents. The invention further provides methods of preparation and methods ... 08/31/06 - 20060194742 - Pyrane derivatives as both ace- and nep-inhibitors wherein R, R1-R7 and alk have meaning as defined, pharmaceutical compositions thereof, and use thereof for the treatment and/or prevention of cardiovascular disorders responsive to ACE and NEP inhibition and/or ECE inhibition. ... 08/31/06 - 20060194741 - Dimeric iap inhibitors Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of ... 08/31/06 - 20060194740 - Nod1 as an anti-tumor agent The invention provides compositions and methods for treating tumors that involve increasing the expression of Nod1 and/or the activity of NOD1. ... 08/17/06 - 20060183695 - Methods of increasing endogenous erythropoietin (epo) The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds. ... 08/17/06 - 20060183694 - Hepatitis c virus inhibitors The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the function of the NS3 protease (also referred to herein as “serine protease”) encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS3 protease. ... 08/17/06 - 20060183693 - Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine A method of treatment or prevention of headache, migraine or cluster headaches, which method comprises co-administration of a therapeutically effective amount of the compound 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine [BIBN4096BS] or a physiologically acceptable salt thereof and a therapeutically effective amount of a second active antimigraine drug, particularly sumatriptan, zolmitriptan or dihydroergotamin or a ... 08/17/06 - 20060183692 - Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy According to the invention there is provided a cholesterol lowering therapy method and a method for modification of lipid (triglyceride), lipoprotein, and apolipoprotein profiles associated with an increased risk of cardiovascular complications comprising the administration of a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, to a ... 08/10/06 - 20060178317 - Methods of increasing endogenous erythropoietin (epo) The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds. ... 08/10/06 - 20060178316 - Methods of increasing endogenous erythropoietin (epo) The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds. ... 08/10/06 - 20060178315 - Irreversible cysteine protease inhibitors of legumain Presented are compounds represented by the following general formulas (I) and (II), for inhibiting cysteine protease legumain for modulating associated disease states in subjects. ... 07/27/06 - 20060166897 - Novel indazole peptidomimetics as thrombin receptor antagonists The invention is directed to novel indazole peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, Angiogenesis related disorders, cancer, and neurodegenerative disorders. Pharmaceutical compositions comprising the substituted indazole peptidomimetics of ... 07/27/06 - 20060166896 - Novel indazole peptidomimetics as thrombin receptor antagonists The invention is directed to novel indazole peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, Angiogenesis related disorders, cancer, and neurodegenerative disorders. Pharmaceutical compositions comprising the substituted indazole peptidomimetics of ... 07/27/06 - 20060166895 - Retroviral protease inhibitors N-heterocyclic moiety containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. ... 07/27/06 - 20060166894 - Ace-inhibitors having antioxidant and no-donor activity Multifonctional ACE inhibitor compounds are provided, that combine ACE-inhibiting activity with capability to scavenge superoxide and other reactive oxygen species, and that may further function as nitric oxide donors. The compounds are useful for preventing or treating various disorders, including cardiovascular, and diabetes associated disorders. ... 07/27/06 - 20060166893 - Novel 2-hydroxytetrahydrofurane derivatives and use thereof as medicaments with the substituents as defined in the specification, having a calpain inhibiting activity and/or an activity which traps the reactive oxygen species useful for treating inflammatory and immunological diseases, cardio-vascular and cerebro-vascular diseases, disorders of the central or peripheral nervous system, osteoporosis, muscular dystrophy, proliferative diseases, cataract, rejection reactions following ... 06/22/06 - 20060135438 - Peptidyl prodrugs that resist p-glycoprotein mediated drug efflux Amino acid ester, dipeptide, and tripeptide ester derivatives of bioactive agents are provided wherein said parent agents are substrates effluxed by the P-gp transporter. The derivatives are useful in treating the same condition as the bioactve agent. Also disclosed is a method for preparing a bioactive agent for targeted delivery ... 06/22/06 - 20060135437 - Novel use of peptide compounds for treating pain in trigeminal neuralgia The present invention is directed to the use of a class of peptide compounds for treating pain in trigeminal neuralgia. ... 06/15/06 - 20060128634 - Alpha, alpha-disubstituted benzylglycine derivatives as hiv protease inhibitors or a stereoisomeric form, a mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof, which are useful as HIV protease inhibitors, pharmaceutical compositions and diagnostic kits including the same, methods for using the same for treating viral infection or an assay standards or reagents, and intermediates and processes for ... 06/08/06 - 20060122125 - Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof The present invention provides cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, methods of making cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs and compositions of cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs. The present invention also provides methods of using cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs and compositions of cyclic 1-(acyloxy)-alkyl prodrugs of GABA ... 06/08/06 - 20060122124 - Therapeutic agent R2 is lower alkyl, lower alkoxy or benzyl and n is 0-3, or a pharmaceutically acceptable salt or mono- or diester thereof. ... 06/01/06 - 20060116328 - Combined use of carnosinase inhibitor with l-carnosines and composition The present invention provides combined use of a carnosinase inhibitor with L-carnosine and its related substance, and a composition containing the same, which are useful for treatment or prevention of various diseases, improvement of health conditions, improvement of exercise ability, improvement of skin health, prevention of the side effects of ... 05/25/06 - 20060111304 - Anthranyl derivatives having an anticholecystokinin activity (anti-cck-1), a process for their preparation, and pharmaceutical use thereof Anthranylic compounds having anti-CCK activity of general formula (I) in which, n is a whole number lying between 0 and 7; R1 is chosen independently from the groups (II), in which X1 is chosen independently from, S, O, NR2 and X2 is a group chosen from: H, C1-C4 alkyl, F, ... 05/25/06 - 20060111303 - Diketohydrazine derivative compounds and drugs contaiing the compounds as the active ingredient The compound of formula (I) has an inhibitory activity against cysteine protease, and it is useful for the treatment of inflammatory diseases, immune diseases, ischemic diseases, respiratory diseases, circulatory diseases, blood diseases, neuronal diseases, hepatic or biliary diseases, osseous or articular diseases, metabolic diseases, etc. And the compound has inhibitory ... 05/11/06 - 20060100161 - Mitotic kinesin inhibitors and methods of use thereof This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders. ... 05/11/06 - 20060100160 - Amino acid derived prodrugs of propofol, compositions and uses thereof The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting. ... 05/04/06 - 20060094665 - Pharmaceutical angiostatic dipeptide compositions and methods of use thereof Disclosed are methods of inhibiting neovascularization in a subject by administering to the subject a pharmaceutical preparation of R′-Glu-Trp-R″. ... 04/13/06 - 20060079463 - Anticancer compositions comprising methenamine The invention is directed to anti-cancer compositions comprising methenamine or its derivatives or conjugates, and to use of such methenamine containing compositions to treat cancer. ... 03/30/06 - 20060069038 - Irreversible caspase-3 inhibitors as active site probes The present invention encompasses a compound of Formula (I) useful as caspase active site probes. These probes can be used to determine whether a caspase has been activated, in cells or in tissues of animal models of various pathologies. Furthermore, through competition based assays, these caspase active site probes can ... 03/23/06 - 20060063719 - Methods for treating diabetes The invention relates to compositions of Glu-boroPro and methods of use thereof in the prevention or management of type 2 diabetes. ... 03/16/06 - 20060058242 - Dipeptide derivatives wherein R, R1, COOR2, R3-R7, alk, and X have meaning as defined, such being useful as dual inhibitors of angiotensin converting enzyme and neutral endopeptidase, as well as inhibitors of endothelin converting enzyme. ... 03/09/06 - 20060052315 - Cb 1/cb 2 receptor ligands and their use in the treatment of pain Compounds of formula (I) or pharmaceutically acceptable salts thereof wherein Ar1?, Ar2?, R1?, R2?, n and X are as defined in the specifications well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain. ... 03/09/06 - 20060052314 - Pharmaceutical combination There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivateive thereof) or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 or WO 01/28993 or (2) compound of claim ... 03/09/06 - 20060052313 - Selective dipeptide inhibitors of kallikrein R5 is selected from lower alkyl, phenyl and benzyl. The compounds are useful as pharmaceutical compositions. ... 03/02/06 - 20060046967 - Prodrugs containing novel bio-cleavable linkers The invention provides the compounds of formula (I) or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one more of pharmaceutically acceptable carriers, vehicles or diluents. The invention further provides methods of preparation and methods of ... 03/02/06 - 20060046966 - Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis wherein the formula variables are as defined in the disclosure, advantageously inhibit or block the biological activity of the picornaviral 3C protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with one or more picornaviruses, such as RVP. Intermediates and ... 03/02/06 - 20060046965 - Hepatitis c inhibitor dipeptide analogs wherein R1, R2, R3, R4, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease. ... 02/23/06 - 20060040872 - Calcium channel inhibitor The present invention relates to an agent which inhibits or suppresses calcium channel where dipeptide Val-Tyr (VY) or a substance containing the same is an effective ingredient. Examples of the substance containing VY are hydrolysate (sardine peptide) of fish meat of sardine, etc., and VY or VY-containing substance is also ... 02/23/06 - 20060040871 - Bacterial transforming agent A method of increasing the sensitivity of a bacterial strain to a cell-wall active antimicrobial agent, to which the bacterial strain or a progenitor strain from which the bacterial strain has evolved is sensitive is described. The method comprises the step of exposing said bacterial strain to a transforming agent ... 02/02/06 - 20060025347 - Iap binding compounds IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less that 0.1 micromolar. Methods of using ... 02/02/06 - 20060025346 - Permeability enhancer The present invention provides an enhancer for the absorption by membrane permeation of low molecular weight substances. An enhancer for the absorption of low molecular weight substances by membrane permeation comprising poly-γ-glutamic acid as an active ingredient, and a composition characterized by comprising poly-γ-glutamic acid and a functional food component ... 02/02/06 - 20060025345 - Substituted ethane-1,2-diamines for the treatment of alzheimer's disease wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, A, B, and Y are defined as in the specification and claims and to its use for treating or preventing Alzheimer's disease and other similar diseases. ... 01/19/06 - 20060014701 - Novel amide derivatives as growth hormone secretagogues wherein n is an integer from 0-4, R4 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, R5 and R6 are independently selected from hydrogen, substituted or unsubstituted alkyl, or R5 and R6 or R4 and R5 are taken together to form substituted or unsubstituted ... 01/19/06 - 20060014700 - Inhibitors of iap wherein X, Y, A, R1, R2, R3, R4, R4′, R5, R5′, R6 and R6′ are as described herein. ... 01/19/06 - 20060014699 - Aqueous pharmaceutical formulaton comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture of a medicament for use by nasal administration in treating thromboembolism An aqueous pharmaceutical formulation comprising the thrombin inhibitor HOOC—CH2—(R)-Cgl-Aze-Pab (melagatran), or a pharmaceutically-acceptable derivative thereof, a process for the preparation of such a pharmaceutical formulation, the use of such a formulation in the treatment of thromboembolism as well as a method of treating a patient in need of antithrombotic treatment ... 01/12/06 - 20060009397 - New use According to the invention there is provided a kit of parts comprising: (a) a pharmaceutical formulation including a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; and (b) a pharmaceutical formulation including a prodrug of a low ... 01/05/06 - 20060003944 - Bacterial efflux pump inhibitors and methods of treating bacterial infections This invention relates to the field of antimicrobial agents and more specifically it relates to Efflux Pump Inhibitor (EPI) compounds to be co-administered with antimicrobial agents for the treatment of infections caused by drug resistant pathogens. The EPI compounds are soft drugs which exhibit a reduced propensity for tissue accumulation. ... 12/29/05 - 20050288234 - Novel use of peptide compounds for treating essential tremor and other tremor syndromes The present invention is directed to the use of a class of peptide compounds for treating essential tremor and other tremor syndromes. ... 12/29/05 - 20050288233 - Novel compounds as inhibitors of hepatitis c virus ns3 serine protease The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease. ... 12/29/05 - 20050288232 - Proline ester and preparation containing the same for percutaneous administration The proline ester (I) of the present invention and a pharmaceutically acceptable salt thereof are useful as a prodrug of enalaprilat, which is a medicine useful for preventing or treating circulatory diseases such as hypertension, cardiac diseases (e.g., cardiac hypertrophy, cardiac failure, and myocardial infarct), nephritis, and apoplexy. Thus, a ... 12/15/05 - 20050277597 - Use of n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester to treat sunburn and other burns A method and formulation for treating skin for sunburn and other types of burns is disclosed. The method comprises the topical application of a preparation comprising N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester and its lower alkyl ester derivatives. ... 12/15/05 - 20050277596 - Novel use of peptide compounds for treating amyotrophic lateral sclerosis The present invention is directed to the use of a class of peptide compounds for treating amyotrophic lateral sclerosis (ALS) and other forms of motoneuron diseases and peripheral neuropathies. ... 12/08/05 - 20050272668 - Anti-inflammatory compositions and methods The disclosed invention includes pharmaceutical compositions and methods for treating inflammatory conditions, particularly those that are characterized by increased binding of alpha-9 integrin to one or more of its ligands. Also disclosed are methods for selecting compounds for use in such compositions and methods. ... 12/08/05 - 20050272667 - Analogs and derivatives of (s,s,r)-(-)-actinonin and uses therefor where R1 is hydrogen, C(O)R6 or R1 in combination with N is 2-oxomorpholine, R2 is hydrogen, methyl, CH2CH(CH3)2, (CH2)2CH3, CH(CH3)2, (CH2)3CH3, (CH2)4NH2, (CH2)3CO2H, phenyl, 3,4-dichlorophenyl, biphenyl, benzyl, 4-hydroxybenzyl, piperidine, N-Boc-4-piperidine, CH2-(N-Boc-4-piperidine), 4-tetrahydropyran, CH2-4-tetrahydropyran, 3-methyl indolyl, 2-naphthyl, 3-pyridyl, 4-pyridyl, 3-thienyl, R3 is R2 or C3-8alkyl, R4 is C1-3alkyl, R5 is NH2, ... 12/08/05 - 20050272666 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical ... 12/01/05 - 20050267044 - Novel compounds and compositions as cathepsin s inhibitors The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making. ... 12/01/05 - 20050267043 - Novel inhibitors of hepatitis c virus ns3 protease The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease. ... 12/01/05 - 20050267042 - Method and preparation for binding acetaldehyde in saliva, stomach and large intestine The object if the invention is the use of compounds comprising one or more free sulphlydryl or amino groups for preparing a pharmaceutical composition for locally binding acetaldehyde in saliva, the stomach or the large intestine, and pharmaceutical compositions comprising the said compounds. ... 11/24/05 - 20050261204 - Novel use of peptide compounds for treating dyskinesia The present invention is directed to the use of a class of peptide compounds for treating primary or/and secondary dyskinesias such as tardive dyskinesia. ... 11/24/05 - 20050261203 - Azabicyclo-octane inhibitors of iap X1 and X2 are independently O or S; L is a bond or —C(X3)—, —C(X3)NR12, —C(X3)O— wherein X3 is O or S and R12 is H or R1; R1 is alkyl, a carbocycle, carbocycle-substituted alkyl, a heterocycle or heterocycle-substituted alkyl, wherein each is optionally substituted with halogen, hydroxyl, mercapto, carboxyl, ... 11/10/05 - 20050250707 - Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing ... 11/10/05 - 20050250706 - Processes for the preparation of alpha polymorph of perindopril erbumine Processes for the preparation of an alpha polymorph of perindopril erbumine is provided comprising (a) forming a solution comprising perindopril erbumine in one or more ketones; (b) heating the solution to reflux; and (c) cooling the solution to a temperature sufficient to form the alpha polymorph of perindopril erbumine. The ... 11/03/05 - 20050245458 - Novel compounds as inhibitors of hepatitis c virus ns3 serine protease The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease. ... 11/03/05 - 20050245457 - Pseudopeptides growth hormone secretagogues The present invention relates to novel growth hormone releasing pseudopeptides capable of stimulating the release of growth hormone from the pituitary and of promoting growth in mammals. The invention also provides pharmaceutical compositions comprising the pseudopeptides growth hormone secretagogues and a method for promoting the release of growth hormone in ... 10/27/05 - 20050239716 - 2-{[n-(2-amino-3-(heteroaryl or aryl) propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives wherein the substituents are as defined in the description, to processes for the preparation thereof, to pharmaceutical preparations comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans. ... 10/27/05 - 20050239715 - Inhibition of allergic contact dermatitis by n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester It has now been found that N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester (APM) and/or one of its lower alkyl derivatives can be used to treat allergic contact dermatitis associated with irritating oils such as catechol-containing plant-derived antigens such as poison ivy, poison oak, poison sumac and Asian lacquer tree and oils containing capsaicin. ... 10/27/05 - 20050239714 - Compositions and methods for treating female sexual arousal disorder using hydrophobic-calcitonin gene related peptide The present invention provides a method and composition for the treatment of Female Sexual Arousal Disorder. Calcitonin gene-related peptide, a naturally occurring substance in the human body, is chemically conjugated to a hydrophobic agent thereby increasing its permeability across the skin membrane. When locally applied to female genitalia localized blood ... 10/27/05 - 20050239713 - Novel tubulysin analogues The invention relates to tubulysin derivatives of general formula (II), said derivatives having a cytostatic effect. ... 10/20/05 - 20050233981 - Compounds with growth hormone releasing properties wherein R1, R2, R5, R6, R7, R8, G, J, L, M, a, b, c, d, e, and f are as defined in the specification, and compositions containing them. These compounds are useful for treating medical disorders resulting from a deficiency in growth hormone. ... 10/20/05 - 20050233980 - Cgrp-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine The present invention relates to a process for the treatment or prevention of headaches, migraine or cluster headache, this process comprising the joint administration of a therapeutically effective amount of the CGRP-antagonist (A) or a physiologically acceptable salt thereof and a therapeutically effective amount of the selective serotonin reuptake inhibitor ... 10/20/05 - 20050233979 - Caspase inhibitors and uses thereof wherein the variables are as defined herein. The present invention also provides processes for preparing the compounds of formula I, and intermediates thereof, pharmaceutical compositions comprising those compounds, and methods of using the compounds and compositions. ... 10/20/05 - 20050233978 - Novel inhibitors of dipeptidyl peptidase i and the pharmaceutical salts thereof, in which R is an acyl-residue including urethane and peptide, or a branched or unbranched C1-C9 alkyl chain, a branched or unbranched C2-C9 alkenyl chain, a branched or unbranched C2-C9 alkynyl chain, a C3-C9 cycloalkyl, C4-C9 carbocyclic, C5-C14 aryl, C3-C9 heteroaryl, C3-C9 heterocyclic, all of ... 10/20/05 - 20050233977 - Process of producing ala-gln dipeptide A synthesis method of alanyl-glutamine includes the steps of: The N-terminal protected alanine reacts with triphenylphosphine and hexachloroethane in organic solvent to form active ester, the active ester reacts with glutamine in a solution mixture containing organic solvent and aqueous solution of inorganic base, the resultant mixture is acidified with ... 10/20/05 - 20050233976 - Therapeutic methods The invention provides methods for treating a symptom of MCI as well as methods for slowing the progression from MCI to AD. ... 10/13/05 - 20050227926 - Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors Selected bis-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) ... 10/06/05 - 20050222047 - Novel ketoamides with cyclic p4's as inhibitors of ns3 protease of hepatitis c virus The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease. ... 09/22/05 - 20050209164 - Cyclobutenedione-containing compounds as inhibitors of hepatitis c virus ns3 serine protease The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease. ... 09/22/05 - 20050209163 - Novel use of peptide compounds for treating central neuropathic pain The present invention concerns the use of compounds for treating central neuropathic pain. ... 09/22/05 - 20050209162 - Methods for monitoring il-18 This invention relates to methods for monitoring IL-18. ... 09/15/05 - 20050203031 - Novel antidiabetic agents Compounds which are 1-(2′-aminoacyl)-2-cyanopyrrolidine derivatives according to general formula (1) are DP-IV inhibitors for treatment of impaired glucose tolerance or type 2 diabetes; wherein A is selected from groups (2, 3 and 4); X is selected from aminoacyl groups corresponding to the natural amino acids, acyl groups R3CO, groups R4COOC(R5)(R6)OCO, ... 09/15/05 - 20050203030 - Novel effectors of dipeptidyl peptidase iv Dipeptide compounds and compounds analogous to dipeptide compounds that are formed from an amino acid and a thiazolidine or pyrrolidine group, and salts thereof used in the treatment of impaired glucose tolerance, glycosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy and nephropathy and also of sequelae of diabetes mellitus in ... 09/15/05 - 20050203029 - Agents for treating <i>flaviviridae</i>infections The invention relates to agents for the treatment, therapy and inhibition of Flaviviridae virus infections, which agents comprise proteasome inhibitors as the active component. The agents which are used for inhibiting the release, maturation and replication of Flaviviridae comprise, as the active component in pharmaceutical preparations, substance classes which share ... 09/08/05 - 20050197301 - 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease. ... 09/01/05 - 20050192232 - Novel acyl-dipeptide-like compounds bearing an accessory functional side chain spacer, a method for preparing the same and pharmaceutical compositions containing such products The present invention is directed in particular to dipeptide-like compounds derived from functionally substituted amino acids, having fatty acid chains bound thereto through amidification of the amine functional groups of said dipeptide-like compounds, one end portion of which bears an accessory functional side chain spacer, with the other end portion ... 09/01/05 - 20050192231 - Dipeptide apoptosis inhibitors and the use thereof where R1-R3 and AA are defined herein. The present invention relates to the discovery that compounds having Formula I are potent inhibitors of apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, ... 09/01/05 - 20050192230 - Process for preparing 1- [n²-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine by means of which this compound can be prepared in large amounts, in high yields and with high purity. ... 08/11/05 - 20050176651 - Peptide boronic acids useful in making salts thereof Tripeptide boronic acids of (R,S,R) configuration, for example Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)2, and their use to make base addition salts of such acids. The salts are formulated into anti-thrombotic pharmaceutical formulations. ... 08/04/05 - 20050171025 - Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for treating conditions mediated by DPIV or DPIV-like enzymes, such as cancer and tumors. In a more preferred embodiment, the compounds of the present invention are useful for the ... 08/04/05 - 20050171024 - Modulating angiogenesis The invention provides methods and compositions relating to Kuz involvement in angiogenesis. In various embodiments, the invention provides methods for modulating angiogenesis by specifically modulating the activity of Kuz in a vertebrate animal predetermined to have a pathogenic angiogenesis; methods for modulating angiogenesis by specifically modulating the activity of Kuz ... 08/04/05 - 20050171023 - Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents The use of caspase inhibitors for treating cell death induced by radionuclides, biological agents, or chemical agents is disclosed. In particular, treatment of diseases or conditions caused by exposure to radionuclides, biological agents, or chemical agents, spread of radionuclides, biological agents, or chemical agents, explosion of radionuclides, biological agents, or ... 07/28/05 - 20050164954 - N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient wherein all symbols are the same as described in the specification, and a non-toxic salt thereof. The compound of formula (I) has an inhibitory activity against cysteine protease and therefore it is useful as an agent for the prophylaxis and/or treatment of inflammatory diseases, diseases induced by apoptosis, diseases induced ... 07/28/05 - 20050164953 - Beta-secretase inhibitors The present invention provides compounds that are inhibitors of the proteolytic activity of the enzyme β-secretase, pharmaceutically acceptable salts of the compounds, pharmaceutical compositions comprising the compounds, processes for making the compounds, and methods of using the compounds to treat Alzheimer s disease. ... 07/21/05 - 20050159364 - Copper antagonist compounds Copper antagonist compounds and the use of such compounds in methods for the treatment, prevention, or amelioration of various disorders that would be benefited by reduction in copper, for example copper (II), including neurodegenerative and other disorders. ... 07/21/05 - 20050159363 - Selective neuronal nitric oxide synthase inhibitors Peptidomimetic compositions for selective inhibition of neuronal nitric oxide synthase. ... 07/14/05 - 20050153904 - Dialysis method There is provided the use of a low molecular weight thrombin inhibitor for the manufacture of a medicament for the treatment by dialysis, particularly haemodialysis, of a patient in need of such treatment, in which the thrombin inhibitor is provided in the dialysing solution, as well as dialysing solutions and ... 07/14/05 - 20050153903 - Methods of preparing compounds useful as protease inhibitors that are useful as inhibitors of the HIV protease enzyme. The present invention also relates to intermediate compounds useful in the preparation of compounds of formula (I). ... 07/14/05 - 20050153902 - Inhibitors of integrin avb6 Novel biphenyl derivatives of the general formula I in which R1, R1′, R1″, R2, R2′, R3 and n are as defined in Patent claim 1, stereoisomers thereof and physiologically acceptable salts or solvates thereof are novel integrin inhibitors which preferentially inhibit the αvβ6 integrin receptor. The novel compounds can be ... 06/30/05 - 20050143320 - Protease inhibitors This invention relates to treating an infection with a virus using protease inhibitors. Examples of the protease inhibitors include compounds of formula (II). Each variable is defined in the specification. ... 06/30/05 - 20050143319 - Protease inhibitors This invention relates to treating an infection with a virus using protease inhibitors. Examples of the protease inhibitors include compounds of formula (I). Each variable is defined in the specification. ... 06/30/05 - 20050143318 - Growth hormone secretagogues What is disclosed are growth hormone secretagogues, and their uses, of formula (I) wherein R1 is C6H5CH2OCH2—, C6H5(CH2)3— or indol-3-ylmethyl; Y is pyrrolidin-1-yl, 4-C1-C6 alkylpiperidin-1-yl or NR2R2; R2 are each independently a C1 to C6 alkyl; R3 is 2-napthyl or phenyl para-substituted by W; W is H, F, CF3, C1-C6 ... 06/30/05 - 20050143317 - Compounds and methods for treatment of thrombosis The present invention provides compounds that inhibit Factor XIa and methods of preventing or treating undesired thrombosis by administering a compound of the invention to a mammal. The invention also provides three-dimensional structures of Factor XIa and methods for designing or selecting additional Factor XIa inhibitors using these structures. ... 06/23/05 - 20050137142 - Combinations useful for the treatment of neuronal disorders The present invention provides a method for the treatment of neuronal disorders, in a mammal such as a human, which method comprises administering an effective, non-toxic and pharmaceutically acceptable amount of at least one QC-inhibitor, optionally in combination with at least one agent, selected from the group consisting of PEP-inhibitors, ... 06/23/05 - 20050137141 - Prodrug composition A prodrug composition is provided which includes a pharmaceutical species and an amino acid having a covalent bond to the pharmaceutical species. The pharmaceutical species is characterized by bioavailability of 30% or less and a molecular weight in the range of 100-1000 Daltons. The composition is characterized further in that ... 06/16/05 - 20050130907 - Compounds which can block the response to chemical substances or thermal stimuli or mediators of inflammation of nociceptors, production method thereof and compositions containing same The invention relates to compounds having formula (I), which can block the response to chemical substances or thermal stimuli or mediators of inflammation of nociceptors, a production method thereof and compositions containing same. According to the invention, Ar is a phenyl group substituted with one or more halogen groups; R1 ... 06/09/05 - 20050124554 - Spermidine derivatives for the treatment of chronic neurodegenerative diseases Compounds of the general formula (I): are useful in treating chronic neurodegenerative diseases or conditions in mammals, such as Alzheimer's Disease, Parkinson's Disease, Huntington's Chorea and Multiple Sclerosis. In formula (I), a=3 or 4; b=3 or 4 provided that a+b≦7; c is an integer from 1 to 5; d is ... 06/02/05 - 20050119190 - Inhibitors of the blood-clotting factor xa, production thereof and use of the same The invention relates to novel inhibitors of clotting factor Xa, the preparation and use thereof for therapy, prophylaxis and diagnosis of cardiovascular disorders and thromboembolic events. ... ### FreshPatents.com Support |